Skip to main content

Table 1 Demographic and clinical characteristics

From: Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States

 Before propensity score weightingAfter propensity score weighting with rescaled IPTW*
CharacteristicCetuximab±RT (N = 187)Cisplatin±RT (N = 344)P-valueaCetuximab±RT (N = 263)Cisplatin±RT (N = 268)P-valuea
Age, years  <0.0001  0.902
 Mean (SD)63.9 (9.62)57.4 (8.58) 59.3 (11.69)59.4 (7.70) 
Male, n (%)160 (85.6)281 (81.7)0.256222 (84.4)219 (82.0)0.453
Race, n (%)  0.075  0.298
 White154 (82.4)249 (72.4) 208 (78.9)204 (76.1) 
 Black or African American30 (16.0)83 (24.1) 52 (19.9)54 (20.1) 
 Other1 (0.5)5 (1.5) 1 (0.4)4 (1.5) 
 Undocumented2 (1.1)7 (2.0) 2 (0.8)6 (2.3) 
Ethnicity, n (%)  0.543  0.175
 Hispanic or Latino0 (0)2 (0.6) 0 (0.0)2 (0.7) 
 Not Hispanic or Latino187 (100.0)342 (99.4) 263 (100.0)266 (99.3) 
BMI, kg/m2  0.857  0.773
 Mean (SD)26.7 (6.50)26.8 (6.27) 27.0 (7.45)26.8 (5.41) 
 Median25.726.0 26.626.0 
 Min., max.15.55, 59.4113.62, 49.58 15.55, 59.4113.62, 49.58 
Type of insurance, n (%)  0.054  0.877
 Private, no public48 (25.7)127 (36.9) 84 (32.1)91 (33.8) 
 Public, no private63 (33.7)102 (29.7) 89 (33.9)83 (30.9) 
 Public and private66 (35.3)98 (28.5) 77 (29.1)80 (29.7) 
 Other1 (0.5)6 (1.7) 3 (1.0)5 (1.9) 
 Unknown or undocumented9 (4.8)11 (3.2) 10 (3.9)10 (3.6) 
US region of residence, n (%)  0.005  0.627
 Northeast1 (0.5)2 (0.6) 1 (0.5)1 (0.5) 
 South147 (78.6)304 (88.4) 227 (86.3)226 (84.3) 
 Midwest39 (20.9)37 (10.8) 35 (13.2)39 (14.6) 
 West0 (0.0)1 (0.3) 0 (0.0)2 (0.6) 
Stage of disease at initial diagnosis, n (%)  0.228  0.388
 I3 (1.6)2 (0.6) 5 (2.0)1 (0.5) 
 II3 (1.6)4 (1.2) 2 (0.9)5 (1.7) 
 III55 (29.4)92 (26.7) 74 (28.1)71 (26.6) 
 IV10 (5.3)9 (2.6) 13 (5.0)7 (2.5) 
 IVA98 (52.4)202 (58.7) 140 (53.0)154 (57.7) 
 IVB9 (4.8)26 (7.6) 18 (7.0)22 (8.4) 
 Other1 (0.5)2 (0.6) 1 (0.3)1 (0.5) 
 Undocumented8 (4.3)7 (2.0) 10 (3.8)6 (2.1) 
Tumor location at initial diagnosis, n (%)
 Oral cavity26 (13.9)38 (11.0)0.33434 (12.8)32 (12.0)0.780
 Pharynx119 (63.6)220 (64.0)0.942170 (64.6)171 (63.9)0.868
 Paranasal sinuses0 (0.0)2 (0.6)0.5430 (0.0)3 (1.0)0.110
 Salivary glands1 (0.5)4 (1.2)0.6611 (0.3)3 (1.1)0.250
 Larynx40 (21.4)81 (23.5)0.57258 (22.0)60 (22.4)0.899
 Unknown or undocumented3 (1.6)3 (0.9)0.4304 (1.4)2 (0.8)0.494
HPV results, n (%)  0.361  0.084
 Positive21 (70.0)24 (60.0) 37 (82.9)16 (61.5) 
 Negative7 (23.3)15 (37.5) 6 (13.1)9 (35.8) 
 Undocumented2 (6.7)1 (2.5) 2 (3.9)1 (2.7) 
Tested for p16 status, n (%)  0.0004  0.001
 No/undocumented144 (77.0)213 (61.9) 200 (76.1)169 (63.2) 
 Yes43 (23.0)131 (38.1) 63 (23.9)98 (36.8) 
P16 results, n (%)  0.817  0.104
 Positive30 (69.8)84 (64.1) 53 (77.7)66 (62.4) 
 Negative12 (27.9)44 (33.6) 14 (20.7)38 (35.6) 
 Undocumented1 (2.3)3 (2.3) 1 (1.6)2 (2.1) 
Placement of feeding tube, n (%)  0.398  0.967
 Not placed66 (35.3)109 (31.7) 86 (32.5)88 (32.7) 
 Placed121 (64.7)235 (68.3) 178 (67.5)180 (67.3) 
Smoking status, n (%)  0.073  0.318
 Current72 (38.5)155 (45.1) 111 (42.3)120 (44.8) 
 Past81 (43.3)123 (35.8) 104 (39.6)97 (36.4) 
 Never32 (17.1)66 (19.2) 45 (17.1)50 (18.8) 
 Unknown or undocumented2 (1.1)0 (0.0) 3 (1.0)0 (0.0) 
Alcohol use, n (%)  0.026  0.097
 Current abuse13 (7.0)35 (10.2) 19 (7.2)24 (9.1) 
 Current use67 (35.8)140 (40.7) 99 (37.7)108 (40.5) 
 No current use, no past use46 (24.6)87 (25.3) 67 (25.5)66 (24.8) 
 Past use, no current use31 (16.6)33 (9.6) 45 (17.0)29 (11.0) 
 Past abuse29 (15.5)38 (11.0) 32 (12.1)31 (11.4) 
 Unknown or undocumented1 (0.5)11 (3.2) 1 (0.5)8 (3.2) 
ECOG PS, n (%)  0.355  0.537
 045 (24.1)88 (25.6) 74 (28.1)65 (24.4) 
 134 (18.2)47 (13.7) 40 (15.3)37 (13.8) 
 27 (3.7)13 (3.8) 6 (2.2)12 (4.4) 
 32 (1.1)1 (0.3) 2 (0.7)1 (0.3) 
 41 (0.5)0 (0.0) 1 (0.3)0 (0.0) 
 Undocumented98 (52.4)195 (56.7) 141 (53.5)153 (57.0) 
Composite performance status, n (%)  0.346  0.663
 Impaired11 (5.9)14 (4.1) 10 (4.0)13 (4.7) 
 Not impaired176 (94.1)330 (95.9) 253 (96.0)255 (95.3) 
Weighted index of comorbid conditions, n (%)  <0.0001  0.689
 084 (44.9)220 (64.0) 161 (61.3)155 (57.8) 
 162 (33.2)93 (27.0) 67 (25.4)80 (30.0) 
 223 (12.3)22 (6.4) 21 (8.1)21 (7.9) 
 3–517 (9.1)9 (2.6) 13 (4.9)12 (4.4) 
 6+1 (0.5)0 (0.0) 1 (0.3)0 (0.0) 
  1. *Propensity score modeling led to exclusion of 33 cases within the cetuximab±RT group (trimmed N = 187) and 12 cases within the cisplatin±RT group (trimmed N = 344), leaving an unweighted total sample of 531 patients. Weighting of cases with IPTW altered the implied total sample; therefore, cases were rescaled to produce a sum of weights equal to the trimmed sample of 531. This resulted in weighted study samples across groups that were nearly equal (263 cetuximab±RT, 268 cisplatin±RT)
  2. BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, HPV human papillomavirus, IPTW inverse probability of treatment weight, Max maximum, min minimum, PSM propensity score model, RT radiation therapy, SD standard deviation, US United States
  3. aP-values are from t-test (or Wilcoxon Rank-Sum test, if normality does not hold) for continuous variables or Chi-squared (or Fisher’s Exact test, if expected frequencies are less than 5) for categorical variables